Biochemical Engineering
Pfizer, Valneva boosted by updated Lyme vaccine data

3rd September 2025
Valneva has reported phase 2 data on the third booster dose of its Pfizer-partnered Lyme disease vaccine candidate. Investigators randomized 560 healthy participants to receive vaccine candidate VLA15, given in one of two immunization schedules, or placebo. The analysis of month one data, showed that, after the third booster shot, participants mounted an antibody response against the six serotypes covered by the vaccine candidate. Source: Fierce Biotech 3/9/2025
Back to group news